CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-07-28): Perflubutane improves intra-op ultrasound diagnosis of HCC

Drug & Device Development

Perflubutane improves intra-op ultrasound diagnosis of HCC

Last Updated: 2011-07-28 16:45:24 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Gaseous perflubutane (Sonazoid, GE Healthcare) increases the utility of intraoperative ultrasound during surgery for hepatocellular carcinoma (HCC), Japanese researchers reported online June 20th in Annals of Surgery.

Dr. Junichi Arita of the University of Tokyo and colleagues note that intraoperative ultrasound often finds incidental lesions, but it's difficult to tell which are malignant. Needle biopsies sometimes help, but they have a high false negative rate and can induce tumor seeding.

Intravascular contrast-enhanced intraoperative ultrasound (CE-IOUS) using gaseous sulfur hexafluoride (SonoVue) reportedly helps improve results in such cases. In the current study, the researchers tested another agent, gaseous perflubutane, which improves imaging of Kupffer cells and tumor vascularity.

Altogether 192 patients underwent fundamental intraoperative ultrasound and CE-IOUS. Two Sonazoid injections were allowed per patient. A tentative diagnosis of HCC was made when a lesion was either hypervascular during the vascular phase or hypoechoic during the Kupffer phase.

The results were confirmed up to 12 months postoperatively by means of histological examination or dynamic computed tomography findings.

The fundamental approach spotted 79 new focal liver lesions in 50 patients. Seventeen lesions (22%) were finally diagnosed as HCC. The contrast-enhanced ultrasound identified 21 additional new hypoechoic lesions in 16 patients. Of these, 14 lesions (67%) in 11 patients were finally diagnosed as HCC.

Overall, for distinguishing HCC, CE-IOUS with gaseous perflubutane had a sensitivity of 65%, a specificity of 94% and an accuracy of 87%.

The approach, the authors conclude, is harmless and is effective although the cost (about $65 per injection) puts restraints on its use.

Nevertheless Dr. Arita told Reuters Health by email, "routine use of CE-IOUS using Sonazoid would improve the sensitivity and specificity for diagnosing HCC and would improve disease-free survival rate and, as a consequence, overall survival of patients."

The researchers conclude that "such benefits will need to be confirmed in the future."

SOURCE: http://bit.ly/qGNuct

Ann Surg 2011.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.